<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35379698</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-330X</ISSN><JournalIssue CitedMedium="Internet"><Volume>93</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J Neurol Neurosurg Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Development of a sensitive trial-ready poly(GP) CSF biomarker assay for <i>C9orf72</i>-associated frontotemporal dementia and amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>761</StartPage><EndPage>771</EndPage><MedlinePgn>761-771</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/jnnp-2021-328710</ELocationID><Abstract><AbstractText Label="OBJECTIVE">A GGGGCC repeat expansion in the <i>C9orf72</i> gene is the most common cause of genetic frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). As potential therapies targeting the repeat expansion are now entering clinical trials, sensitive biomarker assays of target engagement are urgently required. Our objective was to develop such an assay.</AbstractText><AbstractText Label="METHODS">We used the single molecule array (Simoa) platform to develop an immunoassay for measuring poly(GP) dipeptide repeat proteins (DPRs) generated by the <i>C9orf72</i> repeat expansion in cerebrospinal fluid (CSF) of people with <i>C9orf72</i>-associated FTD/ALS.</AbstractText><AbstractText Label="RESULTS AND CONCLUSIONS">We show the assay to be highly sensitive and robust, passing extensive qualification criteria including low intraplate and interplate variability, a high precision and accuracy in measuring both calibrators and samples, dilutional parallelism, tolerance to sample and standard freeze-thaw and no haemoglobin interference. We used this assay to measure poly(GP) in CSF samples collected through the Genetic FTD Initiative (N=40 <i>C9orf72</i> and 15 controls). We found it had 100% specificity and 100% sensitivity and a large window for detecting target engagement, as the <i>C9orf72</i> CSF sample with the lowest poly(GP) signal had eightfold higher signal than controls and on average values from <i>C9orf72</i> samples were 38-fold higher than controls, which all fell below the lower limit of quantification of the assay. These data indicate that a Simoa-based poly(GP) DPR assay is suitable for use in clinical trials to determine target engagement of therapeutics aimed at reducing <i>C9orf72</i> repeat-containing transcripts.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Wilson</LastName><ForeName>Katherine M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Katona</LastName><ForeName>Eszter</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glaria</LastName><ForeName>Idoia</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carcol&#xe9;</LastName><ForeName>Mireia</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5054-9016</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swift</LastName><ForeName>Imogen J</ForeName><Initials>IJ</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sogorb-Esteve</LastName><ForeName>Aitana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heller</LastName><ForeName>Carolin</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-1934-6162</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouzigues</LastName><ForeName>Arabella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heslegrave</LastName><ForeName>Amanda J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keshavan</LastName><ForeName>Ashvini</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knowles</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patil</LastName><ForeName>Saurabh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Wave Life Sciences, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohapatra</LastName><ForeName>Susovan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Wave Life Sciences, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yuanjing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Wave Life Sciences, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goyal</LastName><ForeName>Jaya</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Wave Life Sciences, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez-Valle</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Cl&#xed;nic, Institut d'Investigaci&#xf3;ns Biom&#xe8;diques August Pi I Sunyer, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laforce</LastName><ForeName>Robert Jr</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Clinique Interdisciplinaire de M&#xe9;moire, D&#xe9;partement des Sciences Neurologiques, CHU de Qu&#xe9;bec, and Facult&#xe9; de M&#xe9;decine, Universit&#xe9; Laval, Quebec City, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Synofzik</LastName><ForeName>Matthis</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2280-7273</Identifier><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neurodegenerative Diseases, (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>James B</ForeName><Initials>JB</Initials><Identifier Source="ORCID">0000-0001-7216-8679</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust and Medical Research Council Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finger</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-4461-7427</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurological Sciences, University of Western Ontario, University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandenberghe</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Service, University Hospitals, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butler</LastName><ForeName>Christopher R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain Sciences, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerhard</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8071-6062</Identifier><AffiliationInfo><Affiliation>Division of Neuroscience and Experimental Psychology, Wolfson Molecular Imaging Centre, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Geriatric Medicine and Nuclear Medicine, University of Duisburg- Essen, University of Duisburg- Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Swieten</LastName><ForeName>John C</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0001-6278-6844</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seelaar</LastName><ForeName>Harro</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-1989-7527</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borroni</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-9340-9814</Identifier><AffiliationInfo><Affiliation>Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galimberti</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-9284-5953</Identifier><AffiliationInfo><Affiliation>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro Dino Ferrari, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Mendon&#xe7;a</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Lisbon, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masellis</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tartaglia</LastName><ForeName>M Carmela</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Canadian Sports Concussion Project, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otto</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Bioclinicum, Karolinska Institutet, Solna, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit for Hereditary Dementias, Theme Aging, Karolinska University Hospital, Solna, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ducharme</LastName><ForeName>Simon</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7309-1113</Identifier><AffiliationInfo><Affiliation>McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Douglas Mental Health University Institute, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schott</LastName><ForeName>Jonathan M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0003-2059-024X</Identifier><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malaspina</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Barts and The London School of Medicine and Dentistry Blizard Institute, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3930-4354</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyanapalli</LastName><ForeName>Ramakrishna</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Wave Life Sciences, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rohrer</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0002-6155-8417</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isaacs</LastName><ForeName>Adrian M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-6820-5534</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, UCL Queen Square Institute of Neurology, London, UK a.isaacs@ucl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Genetic FTD Initiative (GENFI)</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PG/17/90/33415</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_00005/12</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M008525/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M023664/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_00030/14</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/T046015/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U105597119</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FRONTOTEMPORAL DEMENTIA</Keyword><Keyword MajorTopicYN="N">MOTOR NEURON DISEASE</Keyword></KeywordList><CoiStatement>Competing interests: SP, SM, YL, JG and RB were paid employees of Wave Life Sciences during completion of this work. JDR is on a Medical Advisory Board for Wave Life Sciences. JMS has received research funding from Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly), has consulted for Roche Pharmaceuticals, Biogen, Merck and Eli Lilly, given educational lectures sponsored by GE Healthcare, Eli Lilly, and Biogen, and serves on a Data Safety Monitoring Committee for Axon Neuroscience SE. HZ has served at scientific advisory boards for Alector, Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies and CogRx, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). JBR has provided consultancy unrelated to the current work for Asceneuron, Astex, Biogen, UCB, SV Health, Curasen.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Afonso</LastName><ForeName>S&#xf3;nia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Almeida</LastName><ForeName>Maria Rosario</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderl-Straub</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andersson</LastName><ForeName>Christin</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antonell</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Archetti</LastName><ForeName>Silvana</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arighi</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Balasa</LastName><ForeName>Mircea</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barandiaran</LastName><ForeName>Myriam</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bargall&#xf3;</LastName><ForeName>Nuria</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartha</LastName><ForeName>Robart</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bender</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benussi</LastName><ForeName>Alberto</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertoux</LastName><ForeName>Maxime</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertrand</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bessi</LastName><ForeName>Valentina</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Black</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bocchetta</LastName><ForeName>Martina</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borrego-Ecija</LastName><ForeName>Sergi</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bras</LastName><ForeName>Jose</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brice</LastName><ForeName>Alexis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bruffaerts</LastName><ForeName>Rose</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Camuzat</LastName><ForeName>Agn&#xe8;s</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ca&#xf1;ada</LastName><ForeName>Marta</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cantoni</LastName><ForeName>Valentina</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caroppo</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cash</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Castelo-Branco</LastName><ForeName>Miguel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colliot</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Convery</LastName><ForeName>Rhian</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cope</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Danek</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deramecourt</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fede</LastName><ForeName>Giuseppe Di</ForeName><Initials>GD</Initials></Investigator><Investigator ValidYN="Y"><LastName>D&#xed;ez</LastName><ForeName>Alina</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duro</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fenoglio</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferrari</LastName><ForeName>Camilla</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Catarina B</ForeName><Initials>CB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Freedman</LastName><ForeName>Morris</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fumagalli</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Funkiewiez</LastName><ForeName>Aur&#xe9;lie</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gabilondo</LastName><ForeName>Alazne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gasparotti</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gauthier</LastName><ForeName>Serge</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gazzina</LastName><ForeName>Stefano</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giaccone</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gorostidi</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graf</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greaves</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guerreiro</LastName><ForeName>Rita</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoegen</LastName><ForeName>Tobias</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Indakoetxea</LastName><ForeName>Bego&#xf1;a</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jelic</LastName><ForeName>Vesna</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jiskoot</LastName><ForeName>Lize</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keren</LastName><ForeName>Ron</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuchcinski</LastName><ForeName>Gregory</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Langheinrich</LastName><ForeName>Tobias</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ber</LastName><ForeName>Isabelle Le</ForeName><Initials>IL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lebouvier</LastName><ForeName>Thibaud</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leit&#xe3;o</LastName><ForeName>Maria Jo&#xe3;o</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levin</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Llad&#xf3;</LastName><ForeName>Albert</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lombardi</LastName><ForeName>Gemma</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lombardi</LastName><ForeName>Jolina</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loosli</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maruta</LastName><ForeName>Carolina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mead</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miltenberger</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Minkelen</LastName><ForeName>Rick van</ForeName><Initials>RV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moreno</LastName><ForeName>Fermin</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nacmias</LastName><ForeName>Benedetta</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nelson</LastName><ForeName>Annabel</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nicholas</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>&#xd6;ijerstedt</LastName><ForeName>Linn</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Papma</LastName><ForeName>Janne M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pasquier</LastName><ForeName>Florence</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peakman</LastName><ForeName>Georgia</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pijnenburg</LastName><ForeName>Yolande</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Polito</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Premi</LastName><ForeName>Enrico</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prioni</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prix</LastName><ForeName>Catharina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Redaelli</LastName><ForeName>Veronica</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rinaldi</LastName><ForeName>Daisy</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rittman</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogaeva</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosa-Neto</LastName><ForeName>Pedro</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rossi</LastName><ForeName>Giacomina</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rossor</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santana</LastName><ForeName>Isabel</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santiago</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saracino</LastName><ForeName>Dario</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scarpini</LastName><ForeName>Elio</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sch&#xf6;necker</LastName><ForeName>Sonja</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shafei</LastName><ForeName>Rachelle</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shoesmith</LastName><ForeName>Christen</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sorbi</LastName><ForeName>Sandro</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>T&#xe1;buas-Pereira</LastName><ForeName>Miguel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tagliavini</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tainta</LastName><ForeName>Mikel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taipa</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tang-Wai</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>David L</ForeName><Initials>DL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Timberlake</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tiraboschi</LastName><ForeName>Pietro</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Todd</LastName><ForeName>Emily</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Damme</LastName><ForeName>Philip Van</ForeName><Initials>PV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vandenbulcke</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verdelho</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villanua</LastName><ForeName>Jorge</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Warren</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilke</LastName><ForeName>Carlo</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wlasich</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zulaica</LastName><ForeName>Miren</ForeName><Initials>M</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>5</Day><Hour>5</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35379698</ArticleId><ArticleId IdType="pmc">PMC9279742</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2021-328710</ArticleId><ArticleId IdType="pii">jnnp-2021-328710</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Majounie E, Renton AE, Mok K, et al. . Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 2012;11:323&#x2013;30. 10.1016/S1474-4422(12)70043-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70043-1</ArticleId><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutherford NJ, Heckman MG, DeJesus-Hernandez M. Length of normal alleles of C9ORF72 GGGGCC repeat do not influence disease phenotype. Neurobiol Aging 2012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3617405</ArticleId><ArticleId IdType="pubmed">22840558</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, DeJesus-Hernandez M, Niemantsverdriet E, et al. . Association between repeat sizes and clinical and pathological characteristics in carriers of C9orf72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol 2013;12:978&#x2013;88. 10.1016/S1474-4422(13)70210-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70210-2</ArticleId><ArticleId IdType="pmc">PMC3879782</ArticleId><ArticleId IdType="pubmed">24011653</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck J, Poulter M, Hensman D, et al. . Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. Am J Hum Genet : 2013;92:345&#x2013;53. 10.1016/j.ajhg.2013.01.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2013.01.011</ArticleId><ArticleId IdType="pmc">PMC3591848</ArticleId><ArticleId IdType="pubmed">23434116</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al. . A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72:257&#x2013;68. 10.1016/j.neuron.2011.09.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. . Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011;72:245&#x2013;56. 10.1016/j.neuron.2011.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, Lashley T, Norona FE, et al. . C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathol 2013;126:845&#x2013;57. 10.1007/s00401-013-1200-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1200-z</ArticleId><ArticleId IdType="pmc">PMC3830745</ArticleId><ArticleId IdType="pubmed">24170096</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, Liu Y, Ba&#xf1;ez-Coronel M, et al. . RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A : 2013;110:E4968-77. 10.1073/pnas.1315438110</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1315438110</ArticleId><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Bieniek KF, Zhang Y-J, et al. . Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathol 2013;126:829&#x2013;44. 10.1007/s00401-013-1192-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1192-8</ArticleId><ArticleId IdType="pmc">PMC3830741</ArticleId><ArticleId IdType="pubmed">24129584</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Baughn M, Rigo F, et al. . Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci U S A 2013;110:E4530&#x2013;9. 10.1073/pnas.1318835110</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1318835110</ArticleId><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Simone R, Balendra R, Moens TG, et al. . G-quadruplex-binding small molecules ameliorate C9orf72 FTD/ALS pathology in vitro and in vivo. EMBO Mol Med 2018;10:22&#x2013;31. 10.15252/emmm.201707850</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201707850</ArticleId><ArticleId IdType="pmc">PMC5760849</ArticleId><ArticleId IdType="pubmed">29113975</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang ZF, Ursu A, Childs-Disney JL. The Hairpin Form of r(G 4 C 2) exp in c9ALS/FTD Is Repeat-Associated Non-ATG Translated and a Target for Bioactive Small Molecules. Cell Chem Biol 2019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6386614</ArticleId><ArticleId IdType="pubmed">30503283</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, Zhang P-W, Pham JT, et al. . RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 2013;80:415&#x2013;28. 10.1016/j.neuron.2013.10.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.10.015</ArticleId><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Sareen D, O'Rourke JG, Meera P, et al. . Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9orf72 repeat expansion. Sci Transl Med 2013;5:ra149. 10.1126/scitranslmed.3007529</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3007529</ArticleId><ArticleId IdType="pmc">PMC4090945</ArticleId><ArticleId IdType="pubmed">24154603</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Rourke JG, Bogdanik L, Muhammad AKMG, et al. . C9orf72 BAC transgenic mice display typical pathologic features of ALS/FTD. Neuron 2015;88:892&#x2013;901. 10.1016/j.neuron.2015.10.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.10.027</ArticleId><ArticleId IdType="pmc">PMC4672384</ArticleId><ArticleId IdType="pubmed">26637796</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J, Zhu Q, Gendron TF, et al. . Gain of toxicity from ALS/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-Containing RNAs. Neuron 2016;90:535&#x2013;50. 10.1016/j.neuron.2016.04.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.04.006</ArticleId><ArticleId IdType="pmc">PMC4860075</ArticleId><ArticleId IdType="pubmed">27112497</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Chew J, Stankowski JN, et al. . Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Sci Transl Med 2017;9. 10.1126/scitranslmed.aai7866. [Epub ahead of print: 29 03 2017].</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aai7866</ArticleId><ArticleId IdType="pmc">PMC5576451</ArticleId><ArticleId IdType="pubmed">28356511</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Dodart J-C, Tran H, et al. . Variant-selective stereopure oligonucleotides protect against pathologies associated with C9orf72-repeat expansion in preclinical models. Nat Commun 2021;12:847. 10.1038/s41467-021-21112-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21112-8</ArticleId><ArticleId IdType="pmc">PMC7870851</ArticleId><ArticleId IdType="pubmed">33558503</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J, Rigo F, Prakash TP, et al. . Recognition of c9orf72 mutant RNA by single-stranded silencing RNAs. Nucleic Acid Ther 2017;27:87&#x2013;94. 10.1089/nat.2016.0655</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/nat.2016.0655</ArticleId><ArticleId IdType="pmc">PMC5372765</ArticleId><ArticleId IdType="pubmed">28005462</ArticleId></ArticleIdList></Reference><Reference><Citation>Martier R, Liefhebber JM, Miniarikova J, et al. . Artificial microRNAs targeting C9orf72 can reduce accumulation of Intra-nuclear transcripts in ALS and FTD patients. Mol Ther Nucleic Acids 2019;14:593&#x2013;608. 10.1016/j.omtn.2019.01.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2019.01.010</ArticleId><ArticleId IdType="pmc">PMC6378669</ArticleId><ArticleId IdType="pubmed">30776581</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnan G, Zhang Y, Gu Y, et al. . CRISPR deletion of the C9ORF72 promoter in ALS/FTD patient motor neurons abolishes production of dipeptide repeat proteins and rescues neurodegeneration. Acta Neuropathol 2020;140:81&#x2013;4. 10.1007/s00401-020-02154-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02154-6</ArticleId><ArticleId IdType="pmc">PMC7300081</ArticleId><ArticleId IdType="pubmed">32266467</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto BS, Saxena T, Oliveira R, et al. . Impeding transcription of expanded microsatellite repeats by deactivated Cas9. Mol Cell 2017;68:479&#x2013;90. 10.1016/j.molcel.2017.09.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2017.09.033</ArticleId><ArticleId IdType="pmc">PMC6013302</ArticleId><ArticleId IdType="pubmed">29056323</ArticleId></ArticleIdList></Reference><Reference><Citation>Batra R, Nelles DA, Pirie E, et al. . Elimination of toxic microsatellite repeat expansion RNA by RNA-Targeting Cas9. Cell 2017;170:899&#x2013;912. 10.1016/j.cell.2017.07.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.07.010</ArticleId><ArticleId IdType="pmc">PMC5873302</ArticleId><ArticleId IdType="pubmed">28803727</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmer C, Oeckl P, Weishaupt JH. Poly&#x2010; GP in cerebrospinal fluid links C9orf72 &#x2010;associated dipeptide repeat expression to the asymptomatic phase of ALS / FTD. EMBO Mol Med : 2017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494528</ArticleId><ArticleId IdType="pubmed">28408402</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran H, Moazami MP, Yang H. Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide. Nat Med.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8861976</ArticleId><ArticleId IdType="pubmed">34949835</ArticleId></ArticleIdList></Reference><Reference><Citation>Rissin DM, Kan CW, Campbell TG, et al. . Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 2010;28:595&#x2013;9. 10.1038/nbt.1641</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1641</ArticleId><ArticleId IdType="pmc">PMC2919230</ArticleId><ArticleId IdType="pubmed">20495550</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Nicholas JM, Cash DM, et al. . Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the genetic frontotemporal dementia initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol : 2015;14:253&#x2013;62. 10.1016/S1474-4422(14)70324-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70324-2</ArticleId><ArticleId IdType="pmc">PMC6742501</ArticleId><ArticleId IdType="pubmed">25662776</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, et al. . Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134:2456&#x2013;77. 10.1093/brain/awr179</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr179</ArticleId><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, Hillis AE, Weintraub S, et al. . Classification of primary progressive aphasia and its variants. Neurology 2011;76:1006&#x2013;14. 10.1212/WNL.0b013e31821103e6</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31821103e6</ArticleId><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2000.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong MJ, Litvan I, Lang AE, et al. . Criteria for the diagnosis of corticobasal degeneration. Neurology 2013;80:496&#x2013;503. 10.1212/WNL.0b013e31827f0fd1</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31827f0fd1</ArticleId><ArticleId IdType="pmc">PMC3590050</ArticleId><ArticleId IdType="pubmed">23359374</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;glinger GU, Respondek G, Stamelou M. Clinical diagnosis of progressive supranuclear palsy: the movement disorder Society criteria. Mov Disord 2017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5516529</ArticleId><ArticleId IdType="pubmed">28467028</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardoso MJ, Modat M, Wolz R, et al. . Geodesic information flows: Spatially-Variant graphs and their application to segmentation and fusion. IEEE Trans Med Imaging 2015;34:1976&#x2013;88. 10.1109/TMI.2015.2418298</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/TMI.2015.2418298</ArticleId><ArticleId IdType="pubmed">25879909</ArticleId></ArticleIdList></Reference><Reference><Citation>Weston PSJ, Paterson RW, Modat M, et al. . Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes. Alzheimers Dement 2015;1:440&#x2013;6. 10.1016/j.dadm.2015.10.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dadm.2015.10.001</ArticleId><ArticleId IdType="pmc">PMC4691234</ArticleId><ArticleId IdType="pubmed">26835507</ArticleId></ArticleIdList></Reference><Reference><Citation>Woollacott IOC, Nicholas JM, Heslegrave A, et al. . Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup. Alzheimers Res Ther 2018;10:1&#x2013;14. 2018. 10.1186/s13195-018-0405-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-018-0405-8</ArticleId><ArticleId IdType="pmc">PMC6094471</ArticleId><ArticleId IdType="pubmed">30111356</ArticleId></ArticleIdList></Reference><Reference><Citation>X Y. J D, E S, et al. A Simple Approach to Determine a Curve Fitting Model with a Correct Weighting Function for Calibration Curves in Quantitative Ligand Binding Assays. Aaps J 2018;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">29536273</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeter LHH, Gendron TF, Sias AC. Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers. Ann Clin Transl Neurol 2018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5945959</ArticleId><ArticleId IdType="pubmed">29761121</ArticleId></ArticleIdList></Reference><Reference><Citation>Moens TG, Mizielinska S, Niccoli T, et al. . Sense and antisense RNA are not toxic in Drosophila models of C9orf72-associated ALS/FTD. Acta Neuropathol 2018;135:445&#x2013;57. 10.1007/s00401-017-1798-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1798-3</ArticleId><ArticleId IdType="pmc">PMC6385858</ArticleId><ArticleId IdType="pubmed">29380049</ArticleId></ArticleIdList></Reference><Reference><Citation>Quaegebeur A, Glaria I, Lashley T, et al. . Soluble and insoluble dipeptide repeat protein measurements in C9orf72-frontotemporal dementia brains show regional differential solubility and correlation of poly-GR with clinical severity. Acta Neuropathol Commun 2020;8:184. 10.1186/s40478-020-01036-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-01036-y</ArticleId><ArticleId IdType="pmc">PMC7650212</ArticleId><ArticleId IdType="pubmed">33168090</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JW, Devanarayan V, Barrett YC, et al. . Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 2006;23:312&#x2013;28. 10.1007/s11095-005-9045-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-005-9045-3</ArticleId><ArticleId IdType="pubmed">16397743</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier C, Barbier M, Camuzat A, et al. . Relations between C9orf72 expansion size in blood, age at onset, age at collection and transmission across generations in patients and presymptomatic carriers. Neurobiol Aging 2019;74:234.e1&#x2013;234.e8. 10.1016/j.neurobiolaging.2018.09.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.09.010</ArticleId><ArticleId IdType="pubmed">30337192</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>